Search Results - "Rangwala, Reshma A"

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer by Hong, David S, Concin, Nicole, Vergote, Ignace, de Bono, Johann S, Slomovitz, Brian M, Drew, Yvette, Arkenau, Hendrik-Tobias, Machiels, Jean-Pascal, Spicer, James F, Jones, Robert, Forster, Martin D, Cornez, Nathalie, Gennigens, Christine, Johnson, Melissa L, Thistlethwaite, Fiona C, Rangwala, Reshma A, Ghatta, Srinivas, Windfeld, Kristian, Harris, Jeffrey R, Lassen, Ulrik Niels, Coleman, Robert L

“…Tissue factor (TF) is a potential target in cervical cancer, as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a…”
Get full text

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial by de Bono, Johann S, Concin, Nicole, Hong, David S, Thistlethwaite, Fiona C, Machiels, Jean-Pascal, Arkenau, Hendrik-Tobias, Plummer, Ruth, Jones, Robert Hugh, Nielsen, Dorte, Windfeld, Kristian, Ghatta, Srinivas, Slomovitz, Brian M, Spicer, James F, Yachnin, Jeffrey, Ang, Joo Ern, Mau-Sørensen, Paul Morten, Forster, Martin David, Collins, Dearbhaile, Dean, Emma, Rangwala, Reshma A, Lassen, Ulrik

“…Tisotumab vedotin is a first-in-human antibody–drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is…”
Get full text

Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial by Herzog, Thomas J, Kutarska, Elżbieta, Bidzińsk, Mariusz, Symanowski, Jim, Nguyen, Binh, Rangwala, Reshma A, Naumann, R Wendel

“…This exploratory analysis evaluated the incidence of adverse events (AEs) by folate receptor (FR) status in the randomized, multicenter, open-label PRECEDENT…”
Get more information

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140) by Shah, Neil J., Beckermann, Katy, Vogelzang, Nicholas J., Mao, Shifeng S., Ornstein, Moshe Chaim, Hammers, Hans J., Gao, Xin, McDermott, David F., Haas, Naomi B., Yan, Hongxia, Esquibel, Vanessa, Rangwala, Reshma A., Campbell, Matthew T

“…4511 Background: AXL is up-regulated by hypoxia-inducible factor-1 signaling in both VHL-deficient and hypoxic tumor cells and plays a critical role in the…”
Get full text

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140) by Beckermann, Katy, Shah, Neil J., Vogelzang, Nicholas J., Mao, Shifeng S., Ornstein, Moshe Chaim, Hammers, Hans J., Gao, Xin, McDermott, David F., Haas, Naomi B., Yan, Hongxia, Esquibel, Vanessa, Rangwala, Reshma A., Campbell, Matthew T

“…TPS4599 Background: In clear cell renal cell carcinoma (ccRCC) the constitutive expression of hypoxia induced factor 1-α leads to increased expression of AXL…”
Get full text

Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma by Fuh, Katherine Cynthia, Bookman, Michael A., Coleman, Robert L., Herzog, Thomas J, Thaker, Premal H., Liu, Joyce F., Lane, Michelle W., Rangwala, Reshma A., McIntyre, Gail, Monk, Bradley J., Moore, Kathleen N.

“…Abstract only 5566 Background: AVB-500 is a first-in-class Fc fusion protein that binds the GAS6 ligand thereby inhibiting AXL signaling. Both GAS6 and AXL are…”
Get full text

Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208) by Mahdi, Haider, Schuster, Steven Robert, O'Malley, David M., McNamara, Donna M., Rangwala, Reshma A., Liang, Shang-Ying, Jain, Shweta, Nicacio, Leonardo, Chon, Hye Sook

“…Abstract only TPS5602 Background: Ovarian cancer (OC) is the most lethal gynecologic cancer, accounting for ≈185,000 deaths worldwide in 2018. Most patients…”
Get full text

A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004) by Fuh, Katherine Cynthia, Herzog, Thomas J., Moore, Kathleen N., Myers, Tashanna K. N., Rimel, BJ, Liu, Joyce F., Secord, Angeles Alvarez, Hamilton, Erika P., Reid, Thomas J., Lewin, Sharyn Nan, Mullen, Mary M, Mills, Kathryn A., Anderson, Randy, Rangwala, Reshma A.

“…Abstract only TPS5605 Background: The AXL receptor and its activating ligand, GAS6, are important drivers of metastasis and therapeutic resistance in human…”
Get full text

SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors by Hong, David S., Tehrani, Omid S., Safran, Howard, Steuer, Conor Ernst, Lacy, Jill, Taylor, Matthew H., George, Thomas J., Rangwala, Reshma A., Jain, Shweta, Viana Nicacio, Leonardo, Cho, May Thet

“…Abstract only TPS3160 Background: Tisotumab vedotin (TV) is being developed for patients with cervical cancer and other solid tumors known to express Tissue…”
Get full text

Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC) by Mok, Tony, Wu, Yi-Long, Watson, Patricia A, Zhang, Jin, Rangwala, Reshma A., Lopes, Gilberto

“…Abstract only…”
Get full text

Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1 + ) advanced ovarian cancer: Updated analysis of KEYNOTE-028 by Varga, Andrea, Piha-Paul, Sarina Anne, Ott, Patrick Alexander, Mehnert, Janice M., Berton-Rigaud, Dominique, Morosky, Anne, Zhao, Guo Qing, Rangwala, Reshma A., Matei, Daniela

“…Abstract only 5513 Background: Overexpression of the PD-1 ligand PD-L1 has been demonstrated in ovarian cancer and may hinder an effective antitumor immune…”
Get full text

A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer by Coleman, Robert L., Concin, Nicole, Herzog, Thomas J., Woelber, Linn Lena, Mirza, Mansoor Raza, Monk, Bradley J., Cibula, David, Lorusso, Domenica, González-Martín, Antonio, Windfeld, Kristian, Lammerts van Bueren, Jeroen, Vindeloev, Signe Diness, Rangwala, Reshma A., Vergote, Ignace

“…Abstract only…”
Get full text

KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1) by Brahmer, Julie R., Kim, Edward S., Zhang, Jin, Smith, Margaret Marie, Rangwala, Reshma A., O'Brien, Mary E.R.

“…Abstract only…”
Get full text

Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024 by Brahmer, Julie R., Rodriguez-Abreu, Delvys, Robinson, Andrew George, Hui, Rina, Csõszi, Tibor, Fülöp, Andrea, Gottfried, Maya, Peled, Nir, Tafreshi, Ali, Cuffe, Sinead, O'Brien, Mary, Rao, Suman, Hotta, Katsuyuki, Leiby, Melanie A., McLean, Jessica, Shentu, Yue, Rangwala, Reshma A., Reck, Martin

“…Abstract only 9000 Background: In KEYNOTE-024 (NCT02142738), pembrolizumab (pembro) was superior to chemotherapy (chemo) as first-line (1L) therapy for…”
Get full text

Adverse event profile by therapy cycle for vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD alone in platinum-resistant ovarian cancer by Symanowski, James Thomas, Kutarska, Elzbieta, Bidzinski, Mariusz, Nguyen, Binh, Rangwala, Reshma A., Naumann, R. Wendel

“…Abstract only 5572 Background: Vintafolide (EC145), a folic acid/desacetylvinblastine conjugate, binds with high affinity to folate receptors expressed in…”
Get full text

Abstract CT104: Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001 by Garon, Edward B., Rizvi, Naiyer, Hui, Rina, Leighl, Natasha B., Balmanoukian, Ani S., Eder, Joseph P., Patnaik, Amita, Aggarwal, Charu, Gubens, Matthew A., Horn, Leora, Carcereny, Enric, Ahn, Myung-Ju, Felip, Enriqueta, Lee, Jong-Seok, Zhang, Jin, Rangwala, Reshma A., Lubiniecki, Gregory M., Roach, Charlotte M., Emancipator, Kenneth, Gandhi, Leena

“…Abstract Background: Preliminary KEYNOTE-001 data showed that the PD-1 inhibitor pembro has manageable safety and antitumor activity in previously treated and…”
Get full text

Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1–positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001 by Rizvi, Naiyer A., Garon, Edward B., Leighl, Natasha, Hellmann, Matthew David, Patnaik, Amita, Gandhi, Leena, Eder, Joseph Paul, Rangwala, Reshma A., Lubiniecki, Gregory, Zhang, Jin, Emancipator, Kenneth, Roach, Charlotte M., Rutledge, Ruth, Hui, Rina, Ahn, Myung-Ju, Horn, Leora, Felip, Enriqueta, Carcereny Costa, Enric

“…Abstract only…”
Get full text